Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orion Genomics LLC

www.oriongenomics.com

Latest From Orion Genomics LLC

Deals Shaping the Medical Industry (09/2010)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Novartis Follows Its Own Business Development Model into Molecular Diagnostics

Novartis is mirroring its approach to pharma R&D and leveraging the byproducts of its biomarker work there to build a commercial molecular diagnostics franchise. The head of the unit talks about its structure, strategy and programs.
Medical Device Strategy

Women's Health: A Growing Market for Diagnostic Players

Women's health is an area long shunned by pharmaceutical and diagnostic companies. But that is starting to change thanks to the successes of companies such as Cytyc and Digene, who have built successful testing franchises in the Ob/ Gyn market. As companies such as PerkinElmer and others look to develop new tests in this market, a spate of start-ups are developing technologies that might fit the bill. Of greatest interest are the so-called molecular tests since they offer the advantage of premium pricing.
Medical Device Platform Technologies

Molecular Dx as a Hot Spot

Although it's still a small portion of the $30-plus billion diagnostic services and test supplies business, molecular diagnostics is on disproportionately rapid growth curve. Some estimate its revenue growth at 25% a year compared to the overall industry average of 3-5%. Reimbursement is improving and robust new tests are emerging, slowly but steadily.
Medical Device Innovation
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Research, Analytical Equipment & Supplies
    • PCR & Amplification Tools
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Orion Genomics LLC
  • Senior Management
  • Nathan D Lakey, Pres. & CEO
    Jared Ordway, PhD, Dir., R&D
  • Contact Info
  • Orion Genomics LLC
    Phone: (314) 615-6977
    4041 Forest Park Ave.
    St. Louis, MO 63108
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register